



(12) Translation of
european patent specification

(11) NO/EP 2485724 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/185 (2006.01)
A61P 3/10 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.06.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.02.10
(86)	European Application Nr.	10768898.8
(86)	European Filing Date	2010.10.06
(87)	The European Application's Publication Date	2012.08.15
(30)	Priority	2009.10.06, EP, 09172365
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Dompé farmaceutici s.p.a., Via S. Martino Della Battaglia 12, 20122 Milano, IT-Italia
(72)	Inventor	PIEMONTI, Lorenzo, Diabetes Research Institute (HSR-DRI)San Raffaele Scientific InstituteVia Olgettina 60, I-20132 Milano, IT-Italia DAFFONCHIO, Luisa, c/o Dompé S.p.A.Località Campo di Pile snc, I-67100 L'Aquila AQ, IT-Italia ALLEGRETTI, Marcello, c/o Dompé S.p.A.Località Campo di Pile snc, I-67100 L'Aquila AQ, IT-Italia
(74)	Agent or Attorney	Onsagers AS, Postboks 1813 Vika, 0123 OSLO, Norge


(54) Title **Sulfonamides for the prevention of diabetes**

(56) References
Cited: WO-A2-02/062330
 WO-A2-2009/117710
 US-A1- 2003 216 392
 US-A1- 2004 242 498

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Forbindelse med formel I, eller et farmasøytisk akseptabelt salt derav:



(I)

5

der R er valgt fra lineært eller forgrenet 4-(C₁-C₆)alkyl, 4-trifluormetansulfonyloksy og 3-benzoyl og R¹ er (C₁-C₆)alkyl til anvendelse i forebyggingen av diabetes eller i forsinkelse av fremkomsten av og progresjonen av diabetes.

- 10 2. Forbindelse ifølge krav 1,
der diabetes er Type-1-diabetes.

3. Forbindelse ifølge ethvert av kravene 1 eller 2,
valgt fra R(-)-N-2-[(4-isobutylfenyl)propionyl]-metansulfonamid og R(-)-2-[(4'-
15 trifluormetansulfonyloksy)fenyl]propionyl-metansulfonamid.

4. Forbindelse for anvendelse ifølge ethvert av kravene 1 til 3,
der nevnte salt er valgt fra lysin- og natriumsalter.